If you invested in ImmunityBio, Inc. between 2021 and 2023, you may be eligible to participate in a significant class action settlement. Legal settlements involving biotechnology companies are often complex, but they provide a vital pathway for shareholders to recover financial losses resulting from alleged corporate missteps. Understanding the specifics of the ImmunityBio settlement is the first step toward determining if you have a valid claim and how to proceed with the filing process.
What Is the ImmunityBio Settlement?
The ImmunityBio settlement is a legal resolution to a securities class action lawsuit brought against the company and certain executives. The lawsuit alleged that the company made false or misleading statements regarding its primary drug candidate, N-803 (also known as Anktiva), which was being developed to treat certain types of bladder cancer. Specifically, the plaintiffs claimed that the company failed to disclose manufacturing deficiencies that would eventually lead to a rejection from the U.S. Food and Drug Administration (FDA).
In May 2023, the FDA issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for N-803. This letter indicated that the FDA could not approve the application in its current form due to issues identified during a pre-license inspection of the company’s third-party manufacturing facilities. Following this news, ImmunityBio’s stock price experienced a sharp decline, leading shareholders to seek legal recourse for their financial losses.
The Basis of the Litigation
The core of the legal challenge centered on transparency. In the world of biotechnology, the path to FDA approval is the most critical factor for a company’s valuation. Investors argued that ImmunityBio was not forthcoming about the risks associated with their manufacturing processes. When the FDA’s concerns became public, the resulting market reaction caused significant harm to those who had purchased stock based on the company’s previous optimistic projections.
By reaching a settlement, ImmunityBio does not admit to any wrongdoing. Instead, the settlement represents a compromise intended to avoid the high costs and uncertainties of a prolonged trial. For shareholders, this means a guaranteed fund is now available to distribute among eligible claimants.
Who Is Eligible for Compensation?
Eligibility for a securities settlement is usually defined by a specific timeframe known as the “Class Period.” For the ImmunityBio settlement, the criteria generally apply to individuals and entities who purchased or otherwise acquired ImmunityBio common stock during the period from March 3, 2021, through May 10, 2023, inclusive.
To qualify for a payout, you must have suffered a “recognized loss” as defined by the court-approved Plan of Allocation. This typically means you bought the stock at a price inflated by the alleged misrepresentations and held it until the truth was revealed, resulting in a loss when the stock price dropped. If you sold your shares before the FDA news was released, you might not be eligible, as the legal theory suggests you did not suffer the specific harm addressed by the lawsuit.
Common Eligibility Questions
- Do I need to be a current shareholder? No, you do not need to still hold the stock to be eligible. You simply need to have purchased it during the designated Class Period.
- What if I bought stock through a 401(k)? Participants in retirement plans may be eligible, though the process sometimes involves the plan administrator. It is best to check your individual brokerage statements.
- Are international investors included? Generally, yes, if the shares were traded on a U.S. exchange (like NASDAQ), international investors who bought during the Class Period are usually eligible.
How to File a Claim for the Settlement
Participating in a class action settlement requires proactive steps. You will not automatically receive a check simply because you owned the stock. You must submit a formal document known as a Proof of Claim and Release form. This form serves as your official request for a portion of the settlement fund.
The process of filing can be broken down into three main steps: gathering documentation, completing the form, and submitting by the deadline. Ensuring accuracy in each step is vital to prevent your claim from being rejected or delayed during the auditing process.
Step 1: Gather Your Records
The claims administrator will require proof of your transactions. You should locate your brokerage statements or trade confirmations for the entire Class Period. Specifically, you will need to provide:
- The number of shares purchased or acquired.
- The date of each transaction.
- The price paid per share.
- The number of shares sold, the date of sale, and the price received.
- The number of shares held at the end of the Class Period.
Step 2: Complete the Claim Form
The claim form will ask for your personal contact information and a detailed table of your transactions. Many administrators now offer an online filing portal which is significantly faster and more reliable than paper filing. When filling out the form, ensure that the names on the form match the names on your brokerage accounts exactly.
Step 3: Submit Before the Deadline
Every class action settlement has a strict court-ordered deadline for submissions. If you miss this date, you lose your right to collect any money from the fund. It is highly recommended to submit your claim at least one week before the deadline to account for any technical issues or mailing delays. If filing by mail, use a service that provides tracking and proof of delivery.
Understanding the Payout Process
Many investors wonder exactly how much money they will receive. It is important to manage expectations, as class action settlements rarely cover 100% of an investor’s losses. The ImmunityBio settlement fund, totaling $15 million, will be distributed among all valid claimants after certain costs are deducted.
Deductions from the total fund typically include court-approved attorney fees, reimbursement of litigation expenses, and the costs of notifying shareholders and administering the claims process. The remaining amount, known as the “Net Settlement Fund,” is then divided among claimants based on their “Recognized Loss” amounts.
The Plan of Allocation
The Plan of Allocation is a mathematical formula used to determine each person’s share of the fund. It takes into account when you bought your shares and when you sold them. Because the total value of all valid claims usually exceeds the amount of money in the fund, each claimant receives a “pro-rata” share. This means if the total claims are $100 million and the fund is $10 million, each person might receive approximately 10 cents for every dollar of recognized loss.
Your Legal Rights and Options
When a class action settlement is reached, you generally have three main options. It is important to choose the one that best fits your financial and legal interests. Most people choose to remain in the class and file a claim, but you should be aware of the alternatives.
Option 1: File a Claim
This is the most common path. By filing a claim, you agree to the terms of the settlement and release your right to sue ImmunityBio individually for the same issues in the future. In exchange, you receive a portion of the settlement fund.
Option 2: Exclude Yourself (Opt-Out)
If you have a very large loss and wish to pursue your own private lawsuit against ImmunityBio, you must formally exclude yourself from the class. If you opt-out, you will not receive any money from this settlement, but you retain your right to sue the company on your own. This is usually only practical for institutional investors or individuals with multi-million dollar losses.
Option 3: Object to the Settlement
If you believe the settlement is unfair or that the attorney fees are too high, you can file an objection with the court. You still remain part of the class, but you are asking the judge to reconsider certain aspects of the deal. You must follow specific legal procedures to have your objection heard during the final fairness hearing.
Conclusion and Next Steps
The ImmunityBio settlement offers a measure of recovery for investors who were impacted by the company’s stock volatility following the FDA’s 2023 decision. While the process of filing a claim requires some effort in gathering records and meeting deadlines, it is the only way to ensure you receive your fair share of the settlement fund. If you believe you are eligible, start organizing your brokerage statements today to ensure a smooth filing experience.
For more information on navigating legal claims and protecting your financial interests, explore our other articles on investor rights and consumer protection. Staying informed is your best defense in the complex world of modern finance.